Research programme: peptide therapeutics - Ironwood Pharmaceuticals/Protagonist TherapeuticsAlternative Names: Interleukin 6 peptide antagonists
Latest Information Update: 17 Dec 2014
At a glance
- Originator Ironwood Pharmaceuticals; Protagonist Therapeutics
- Class Peptides
- Mechanism of Action Interleukin 6 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases